Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the his...
Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
About this item
Full title
Author / Creator
Publisher
England: Taylor & Francis Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Taylor & Francis Ltd
Subjects
More information
Scope and Contents
Contents
Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is more effective than its predecessor bicalutamide, which was analyzed in head-to-head studies of patients with CRPC. This family of nonsteroidal antiandrogens is now comprised of...
Alternative Titles
Full title
Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c8829a3407a0460782c8f1334e1272e6
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c8829a3407a0460782c8f1334e1272e6
Other Identifiers
ISSN
2253-2447
E-ISSN
2253-2447
DOI
10.2147/RRU.S157116
